Proposed NIH Cancer Research Cuts Spark Industry ConcernASCOThe Trump administration’s proposed budget cuts to NIH and NCI risk hindering cancer research progress, prompting strong opposition from ASCO and ACS CAN over potential impacts on patient outcomes and innovation.
The Cost of Attacking the Pharmaceutical IndustryTrumpTrump's policies during his second term have rocked the U.S. scientific community, slashing NIH funding, threatening pharmaceutical innovation, and reshaping the global research landscape amid rising concerns about America's future in science.
NIH Cuts and the Future of U.S. BiopharmaNIHTrump's proposed NIH budget cuts, agency consolidations, and funding restrictions could reshape U.S. biomedical research, strain U.S.-China collaborations, and shift national priorities toward AI and space tech.
Trump's Presidency: Impact on the U.S. Biopharma IndustryFDAExplore the implications of Trump's return on U.S. biopharma: healthcare cost reforms, IRA adjustments, reshoring manufacturing, and FDA/NIH shifts. Key focus areas for Chinese pharma include supply chain resilience and navigating new cross-border data regulations.
Tecovirimat Ineffective for Clade I Mpox in DRC StudyNIHA recent NIH study in the Democratic Republic of the Congo found that tecovirimat does not improve clade I mpox lesion resolution. Despite this, mortality rates were lower than average. The study emphasizes the need for more research on effective treatments and vaccines for clade I mpox.
Study Reveals Distinct Long COVID Patterns in Youth: Insights from NIH ResearchNIHAn NIH-supported study published in JAMA uncovers unique long COVID symptom patterns in school-age children and adolescents. The research highlights 18 symptoms in younger children and 17 in adolescents, with significant age-specific differences.
Cabotegravir Safe for HIV Prevention in PregnancyNIHNIH confirms long-acting cabotegravir (CAB-LA) is safe for HIV prevention during pregnancy. The study, with over 300 pregnancies, shows similar maternal and infant outcomes.
Abacavir Linked to Higher Cardiovascular RiskNIHNew analysis from the REPRIEVE trial reveals that the HIV drug abacavir significantly raises the risk of major cardiovascular events. The study highlights no similar risk with other ARVs.
New Target Identified for Dry AMD TreatmentNIHNIH and Johns Hopkins researchers uncover AKT2's role in dry AMD. Their study reveals that lysosomal dysfunction linked to AKT2 may pave the way for new treatments.
EN
Agricultural News
Food News
Industrial News
Cosmetic News
Pharmaceutical News
Science News
